After a prerandomization run-in phase to standardize the background statin-based LDL cholesterol-lowering therapy and to establish participants ' ability to take extended-release niacin without clinically significant adverse effects , we randomly assigned @,@ adults with vascular disease to receive @ g of extended-release niacin and @ mg of laropiprant or a matching placebo daily .